Such investigations could validate or invalidate the hypothesis that AAA-1 assessment in NAFLD can be used to identify the subset of patients particularly likely to benefit from SGLT-2 inhibition. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.